About us
At the Réseau Huntington de Langue Française (RHLF), we are committed to creating impactful solutions to advance research and care for Huntington's disease. Our mission is to drive engagement and innovation by uniting multidisciplinary teams across the biotech and medical fields, ensuring patients and families receive the support they need.
Who We Are
The RHLF was established to address the challenges posed by Huntington's disease, a rare neurodegenerative genetic disorder. By fostering collaboration between researchers, clinicians, and healthcare professionals, we strive to improve care, accelerate research, and create unique opportunities for therapeutic advancements.
Our priority is the well-being of patients and their families, ensuring every decision and initiative aligns with their needs.
Company Réseau Huntington de Langue Française
John Smith, CEO
As founder and visionary of the RHLF, John is passionate about uniting the biotech and medical communities to address the unmet needs of Huntington's disease patients. His leadership drives our mission to improve lives through collaboration and innovation.
Mich Stark, COO
With years of experience in research and development, Mich ensures operational excellence across the network. His strategic insights and dedication to advancing biotechnology have been pivotal to our growth and success.
Aline Turner, CTO
Aline leads a team of 100+ researchers at the forefront of Huntington's disease research. Her commitment to advancing scientific understanding and therapeutic solutions positions the RHLF as a leader in innovation.
Jane Doe, CFO
Jane oversees financial strategies, ensuring sustainable growth and investment in groundbreaking research. Her expertise supports the development of transformative therapies for patients in need.